Laboratory of Veterinary Biochemistry, Department of Veterinary Medicine, Nihon University College of Bioresource Sciences, 1866 Kameino, Fujisawa, Kanagawa, 252-0880, Japan.
Sci Rep. 2018 Jun 4;8(1):8535. doi: 10.1038/s41598-018-26473-7.
The proinflammatory mediator bradykinin stimulated cyclooxygenase-2 (COX-2) expression and subsequently prostaglandin E synthesis in dermal fibroblasts. The involvement of B2 receptors and Gαq in the role of bradykinin was suggested by using pharmacological inhibitors. The PKC activator PMA stimulated COX-2 mRNA expression. Bradykinin failed to induce COX-2 mRNA expression in the presence of PKC inhibitors, whereas the effect of bradykinin was observed in the absence of extracellular Ca. Bradykinin-induced COX-2 mRNA expression was inhibited in cells transfected with PKCε siRNA. These observations suggest that the novel PKCε is concerned with bradykinin-induced COX-2 expression. Bradykinin-induced PKCε phosphorylation and COX-2 mRNA expression were inhibited by an inhibitor of 3-phosphoinositide-dependent protein kinase-1 (PDK-1), and bradykinin-induced PDK-1 phosphorylation was inhibited by phospholipase D (PLD) inhibitors, suggesting that PLD/PDK-1 pathway contributes to bradykinin-induced PKCε activation. Pharmacological and knockdown studies suggest that the extracellular signal-regulated kinase 1 (ERK1) MAPK signaling is involved in bradykinin-induced COX-2 expression. Bradykinin-induced ERK phosphorylation was attenuated in the cells pretreated with PKC inhibitors or transfected with PKCε siRNA. We observed the interaction between PKCε and ERK by co-immunoprecipitation experiments. These observations suggest that PKCε activation contributes to the regulation of ERK1 activation. Bradykinin stimulated the accumulation of phosphorylated ERK in the nuclear fraction, that was inhibited in the cells treated with PKC inhibitors or transfected with PKCε siRNA. Consequently, we concluded that bradykinin activates PKCε via the PLD/PDK-1 pathway, which subsequently induces activation and translocation of ERK1 into the nucleus, and contributes to COX-2 expression for prostaglandin E synthesis in dermal fibroblasts.
炎症介质缓激肽刺激真皮成纤维细胞中环氧化酶-2(COX-2)的表达,随后合成前列腺素 E。使用药理学抑制剂表明 B2 受体和 Gαq 参与了缓激肽的作用。PKC 激活剂 PMA 刺激 COX-2 mRNA 的表达。在 PKC 抑制剂存在的情况下,缓激肽不能诱导 COX-2 mRNA 的表达,而在不存在细胞外 Ca2+的情况下,则观察到缓激肽的作用。在转染 PKCε siRNA 的细胞中,缓激肽诱导的 COX-2 mRNA 表达受到抑制。这些观察结果表明,新型 PKCε 与缓激肽诱导的 COX-2 表达有关。缓激肽诱导的 PKCε 磷酸化和 COX-2 mRNA 表达被 3-磷酸肌醇依赖性蛋白激酶-1(PDK-1)抑制剂抑制,而缓激肽诱导的 PDK-1 磷酸化被磷脂酶 D(PLD)抑制剂抑制,表明 PLD/PDK-1 途径有助于缓激肽诱导的 PKCε 激活。药理学和敲低研究表明,细胞外信号调节激酶 1(ERK1)MAPK 信号转导参与了缓激肽诱导的 COX-2 表达。在用 PKC 抑制剂预处理或转染 PKCε siRNA 的细胞中,缓激肽诱导的 ERK 磷酸化减弱。我们通过共免疫沉淀实验观察到 PKCε 和 ERK 之间的相互作用。这些观察结果表明,PKCε 的激活有助于 ERK1 激活的调节。缓激肽刺激磷酸化 ERK 在核部分的积累,该积累在用 PKC 抑制剂处理或转染 PKCε siRNA 的细胞中受到抑制。因此,我们得出结论,缓激肽通过 PLD/PDK-1 途径激活 PKCε,随后诱导 ERK1 的激活和易位到细胞核中,并有助于真皮成纤维细胞中前列腺素 E 合成的 COX-2 表达。